111782-87-7

Basic information

• Product Name: 4H-Pyran-4-one, 2-ethyl-3-(phenylmethoxy)-
• CAS NO: 111782-87-7
• Molecular Formula: C14H14O3
• Molecular Weight: 230.263
• Mol File: 111782-87-7.mol
• Article Data: 19

Chemical Properties

• CAS DataBase Reference: 4H-Pyran-4-one, 2-ethyl-3-(phenylmethoxy)-(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-Pyran-4-one, 2-ethyl-3-(phenylmethoxy)-(111782-87-7)
• EPA Substance Registry System: 4H-Pyran-4-one, 2-ethyl-3-(phenylmethoxy)-(111782-87-7)

Safety Data

• Hazardous Substances Data: 111782-87-7(Hazardous Substances Data)

Upstream product

• 4940-11-8 2-ethyl-3-hydroxy-4-pyranone 
• 100-44-7 benzyl chloride 
• 100-39-0 benzyl bromide 

Downstream Products

• 123742-56-3 3-benzyloxy-2-ethyl-1-methyl-4(1H)-pyridinone 
• 143697-02-3 2-ethyl-3-(benzyloxy)-4-hydroxypyridine 
• 958753-83-8 5-(benzyloxy)-2-methylpyridin-4(1H)-one 

Relevant articles and documents

CN128: A New Orally Active Hydroxypyridinone Iron Chelator

Deferoxamine, deferiprone, and deferasirox are used for the treatment of systemic iron overload, although they possess limitations due to lack of oral activity, lower efficacy, and side effects. These limitations led to a search for an orally active iron chelator with an improved therapeutic index. The lower efficacy of deferiprone is due to rapid glucuronidation, leading to the formation of a nonchelating metabolite. Here, we demonstrate that the influence of metabolism can be reduced by introducing a sacrificial site for glucuronidation. A log P-guided investigation of 20 hydroxpyridinones led to the identification of CN128. The Fe(III) affinity and metal selectivity of CN128 are similar to those of deferiprone, the log P value is more lipophilic, and its iron scavenging ability is superior. Overall, CN128 was demonstrated to be safe in a range of toxicity assessments and is now in clinical trials for the treatment of β-thalassemia after regular blood transfusion.

Design, synthesis and biological evaluation of hydroxypyridinone-coumarin hybrids as multimodal monoamine oxidase B inhibitors and iron chelates against Alzheimer's disease

A series of hybrids of hydroxypyridinone and coumarin were rationally designed, synthesized and biologically evaluated for their iron ion chelating and MAO-B inhibitory activities. Most of the compounds displayed excellent iron ion chelating effects and moderate to good anti-MAO-B activities. Compound 27a exhibited the most potent activity against MAO-B, with an IC50 value of 14.7 nM. Importantly, 27a showed good U251 cell protective effect and significantly ameliorated the cognitive dysfunction of scopolamine-induced AD mice. Moreover, molecular docking was performed to elucidate the probable ligand-receptor interaction, and the structure-activity relationships were also summarized.

5-aminolevulinic acid/3-hydroxyl pyridone conjugate, preparation method therefor and use of 5-aminolevulinic acid/3-hydroxyl pyridone conjugate

The invention discloses conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one. The conjugates are conjugates of 5-aminolevulinic acid and an iron chelating agent, i.e., 3-hydroxyl pyrid-4-one and are ALA-HPO conjugates 1 to 4 separately. The invention further simultaneously discloses a preparation method for the conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one and use of the conjugates of 5-aminolevulinic acid and 3-hydroxyl pyrid-4-one. The conjugates can be used for preparing photodynamic therapy drugs and can also be used for preparing drugs for treating skin cancer, lung cancer or verruca acuminata.